Fig. 2

RUNX2 expression in cancer depends primarily on HDACs class I. All cell lines were treated for 48 h with low and high doses of HDACs class I specific inhibitors: 4SC-202 (domatinostat, specific for HDAC 1–2-3) PCI-3405 (specific for HDAC8) and TMP269 (specific for class IIa) then RUNX2 levels were assessed by qRT-PCR (a). TPC1 and MDA-MB231 were transfected with siRNA specific for HDAC1, HDAC2, HDAC3 and HDAC8 or with the combination of the former three (b). Histograms represent the mean relative fold change +/− SD of treated /silenced cells compared to the respective control cells. Each experiment represents the average of at least two independent replicates. * p < 0.05